In April, the ACR and the Alzheimer’s Association announced a four-year, $100 million research study to determine the clinical value of brain amyloid PET in diagnosing Alzheimer’s disease and other types of dementia.

The Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) study is an effort to prove to CMS that PET amyloid imaging can lead to improved health outcomes, and therefore warrants coverage.

Source: UBM Partner Site Diagnostic Imaging - For full article, please click here.